Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 32 results
Filters: First Letter Of Last Name is T  [Clear All Filters]
Found 32 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

T

Taiwo B, Zheng L, Gallien S, et al. "Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)." AIDS. 2011;25(17):2113-22.
Taiwo B, Matining RM, Zheng L, et al. "Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy." J. Antimicrob. Chemother.. 2013;68(8):1857-61.
Taiwo BO, Chan ES, Fichtenbaum CJ, et al. "Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study." Clin. Infect. Dis.. 2015;61(7):1179-88.
Taiwo B, Gallien S, Aga E, et al. "Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy." J. Infect. Dis.. 2011;204(4):515-20.
Taiwo B, Hunt PW, Gandhi RT, et al. "CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2013;63(1):101-4.
Tam E, Luetkemeyer AF, Mantry PS, et al. "Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials." Liver Int.. 2017.
Tashima KT, Mollan KR, Na L, et al. "Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity." HIV Clin Trials. 2015;16(4):147-56.
Tashima KT, Smeaton LM, Fichtenbaum CJ, et al. "HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial." Ann. Intern. Med.. 2015;163(12):908-17.
Tassiopoulos K, Abdo M, Wu K, et al. "Frailty is strongly associated with increased risk of recurrent falls among older HIV-infected adults." AIDS. 2017;31(16):2287-2294.
Tassiopoulos K, Landay A, Collier AC, et al. "CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies." J. Infect. Dis.. 2012;205(11):1730-8.
Taylor LE, Holubar M, Wu K, et al. "Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials." Clin. Infect. Dis.. 2011;52(6):812-8.
Tebas P, Zhang J, Yarasheski K, et al. "Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)." J. Acquir. Immune Defic. Syndr.. 2007;45(2):193-200.
Tebas P, Henry WKeith, Matining R, et al. "Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk." PLoS ONE. 2008;3(4):e2021.
Tebas P, Zhang J, Hafner R, et al. "Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110." J. Antimicrob. Chemother.. 2009;63(5):998-1005.
Tenforde MW, Gupte N, Dowdy DW, et al. "C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings." PLoS ONE. 2015;10(2):e0117424.
Tenforde MW, Yadav A, Dowdy DW, et al. "Vitamin A and D Deficiencies Associated With Incident Tuberculosis in HIV-Infected Patients Initiating Antiretroviral Therapy in Multinational Case-Cohort Study." J. Acquir. Immune Defic. Syndr.. 2017;75(3):e71-e79.
Tenorio AR, Spritzler J, Martinson J, et al. "The effect of aging on T-regulatory cell frequency in HIV infection." Clin. Immunol.. 2009;130(3):298-303.
Tenorio AR, Zheng Y, Bosch RJ, et al. "Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment." J. Infect. Dis.. 2014;210(8):1248-59.
Tenorio AR, Jiang H, Zheng Y, et al. "Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115." AIDS Res. Hum. Retroviruses. 2009;25(2):135-9.
Tenorio AR, Chan ES, Bosch RJ, et al. "Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286." J. Infect. Dis.. 2015;211(5):780-90.
Thio CL, Smeaton L, Hollabaugh K, et al. "Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks." AIDS. 2015;29(10):1173-82.
Thio CL, Smeaton L, Saulynas M, et al. "Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort." AIDS. 2013;27(2):191-201.
Thomas AS, Jones KL, Gandhi RT, et al. "T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy." PLoS Pathog.. 2017;13(9):e1006629.
Timmermans EC, Tebas P, Ruiter JPN, Wanders RJA, de Ronde A, de Baar MP. "Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy." Clin. Chem.. 2006;52(6):979-87.
Torriani FJ, Komarow L, Parker RA, et al. "Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s." J. Am. Coll. Cardiol.. 2008;52(7):569-76.
Treasure GC, Aga E, Bosch RJ, et al. "Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials." J. Acquir. Immune Defic. Syndr.. 2016;72(3):310-3.
Tsibris AMN, Paredes R, Chadburn A, et al. "Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211." Clin. Infect. Dis.. 2009;48(5):642-9.
Tsibris AMN, Hu Z, Paredes R, et al. "Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures." J. Virol.. 2012;86(12):6416-26.
Tsibris AMN, Korber B, Arnaout R, et al. "Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo." PLoS ONE. 2009;4(5):e5683.
Tsibris AMN, Sagar M, Gulick RM, et al. "In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject." J. Virol.. 2008;82(16):8210-4.

Pages